Varicella zoster virus the ACIP recommended a second dose of vaccine before school entry to ensure the maintenance of high levels of varicella immunity. In 2006, the United States Food and Drug Administration approved Zostavax for the prevention of shingles. Zostavax is a more concentrated formulation of the Varivax vaccine, designed to elicit an immune response in older adults whose immunity to VZV wanes with advancing age. A systematic review by the Cochrane Library shows that Zostavax reduces the incidence of shingles by almost 50%. Shingrix is a "V. zoster" vaccine developed by GlaxoSmithKline which was approved in the United States by the
Chronic disease in China will mandate an integrated and comprehensive approach to the control and prevention of cardiovascular disease, cancer, chronic respiratory disease, and diabetes. There will be priority actions in at least four areas: adult male smoking, hypertension, overweight and obesity, and capacity building for chronic disease control. The National Center for Chronic and Non-communicable Disease Control and Prevention (NCNCD) was established in 2002, under the leadership of the Chinese Center for Disease Prevention and Control (CDC), which is the technical counterpart of the Ministry of Health. NCNCD is the institution for chronic disease prevention and control at the national level and is